Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may unlock faster POTS diagnosis

NCT ID NCT03218761

Diagnosis Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to validate a blood test that measures NET mRNA levels as a simpler way to assess norepinephrine transporter function in people with Postural Tachycardia Syndrome (POTS). Researchers will compare these levels with traditional measures in 200 participants, including those with POTS and healthy controls. If the test works, it could make diagnosing POTS easier and faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simpler blood test to help diagnose POTS, replacing older, more complex methods.
What could go wrong
This is an early validation study, not a treatment trial. The blood test may not correlate well with actual NET function, limiting its diagnostic value.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2017

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with POTS and Subjects without POTS who are not on drugs that inhibit the norepinephrine transporter and are willing to give their informed consent (or assent and parental consent) to participate in the project.

Ages

13 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Postural Tachycardia Syndrome * Previously diagnosed with POTS • Control Subjects * Not diagnosed with POTS * Age between 13-80 years * Male and female subjects are eligible. * Able and willing to provide informed consent (if ≥18 years) or assent with parental consent (if age 13-17 years) Exclusion Criteria: * • Inability to give, or withdrawal of, informed consent * Use of serotonin-norepinephrine reuptake inhibitors (SNRI) or NET inhibitors within 1 month o These drugs pharmacologically block NET activity * Use of Tricyclic antidepressants within 1 week o Many tricyclic antidepressants pharmacologically block NET activity * Other factors which in the investigator's opinion would prevent the subject from completing the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postural tachycardia syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

postural orthostatic tachycardia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postural tachycardia syndrome

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.